This supports our hypothesis that IL-2Rα-specific antibodies may have differential effects on TRegs and anti-tumor effector T-cells in the milieu of homeostatic cytokines which would be seen in patients treated with lymphodepleting chemotherapies, such as TMZ, which is now standard-of-care for patients with GBM. The gene discussed is IL2RA; the disease is neoplasm.